Like this article?
Get your free daily medical news from Physician's First Watch.
FDA Calls for Boxed Warning on Promethazine Hydrochloride Injection
Injectable promethazine hydrochloride (former brand name, Phenergan) should carry a boxed warning to emphasize the risk for severe tissue injury when the drug is given incorrectly, the FDA announced on Wednesday. (Promethazine is used as a sedative and to treat nausea and vomiting.)
The agency says intramuscular injection is preferable.
Intra-arterial or subcutaneous promethazine injection can result in gangrene and other serious tissue injury, while during intravenous administration, the drug can "leach out" from the vein and harm nearby tissue. Clinicians who choose intravenous delivery should limit the drug's concentration and the speed of administration, the FDA says.
LINK(S):
FDA news release (Free)
Published in Physician's First Watch September 17, 2009
Reader Remarks:
Read all Reader Remarks on this article
- PROMETHEZINE
JANA PALEY, 28 Dec 2009 1:33 AM EST
IS IT POSSIBLE THAT USE OF PROMETHEZINE THROUGH A PICC LINE IN THE LEG (NOT NECESSARILY IN A LARGE VEIN)... [more]
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.